A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico

Last updated: May 31, 2023
Sponsor: Bayer
Overall Status: Completed

Phase

N/A

Condition

Allergy

Common Cold

Nasal Obstruction

Treatment

Online survey

Clinical Study ID

NCT04645979
21614
  • Ages 20-50
  • All Genders

Study Summary

Acute allergic rhinitis is a common allergic reaction to things like pollen or dust. It causes inflammation inside the nose, resulting in symptoms similar to the common cold. Allergic rhinitis is also known as hay fever.

In this study, the researchers want to learn what participants think of betamethasone plus loratadine as a treatment for their acute allergic rhinitis. These participants will have used betamethasone plus loratadine as a treatment for their acute allergic rhinitis within the past two months. During the study, participants will complete an online questionnaire about their experience with betamethasone plus loratadine.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants who used betamethasone plus loratadine within the previous 2 months forthe treatment of acute episodes of allergic rhinitis
  • Participants allowing to use the data for research and marketing purposes as well astalking to authorities
  • Participants allowing us to use the pseudo-randomized individual data for further dataanalysis
  • Able to read and understand the language of the online questionnaire

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 153
Treatment Group(s): 1
Primary Treatment: Online survey
Phase:
Study Start date:
November 11, 2020
Estimated Completion Date:
November 27, 2020

Connect with a study center

  • Many locations

    Multiple Locations,
    Mexico

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.